tbuckley/cabot-search huggingface dataset:
Bone Pain As a Presenting Symptom in Patients with Newly Diagnosed Multiple Myeloma in the Primary Care Setting: A Population-Based Cohort Study
Authors: Anouchka Seesaghur, Natalia Petruski-Ivleva, Victoria Banks, Jocelyn Ruoyi Wang, Pattra Mattox, Ali Abbasi, Joe Maskell, David Neasham, Karthik Ramasamy
Journal: Blood (2020)
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
Authors: Romain Cohen, Jaafar Bennouna, Aurélia Meurisse, Christophe Tournigand, Christelle De La Fouchardière, David Tougeron, Christophe Borg, Thibault Mazard, Benoist Chibaudel, Marie-Line Garcia-Larnicol, Magali Svrcek, Dewi Vernerey, Yves Menu, Thierry André
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC). Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria may underestimate response to ICIs due to the pseudoprogression phenomenon. The GERCOR NIPICOL phase II study aimed to evaluate the frequency of pseudoprogressions in patients with MSI/dMMR mCRC treated with nivolumab and ipilimumab. Methods Patients with MSI/dMMR mCRC previously treated with fluoropyrimidines, oxaliplatin, and irinotecan with/without targeted therapies received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four cycles then nivolumab 3 mg/kg every 2 weeks until progression or a maximum of 20 cycles. Computed tomography scan tumor assessments were done every 6 weeks for 24 weeks and then every 12 weeks. The primary endpoint was disease control rate at 12 weeks according to RECIST 1.1 and iRECIST by central review. Results Of 57 patients included between December 2017 and November 2018, 48.0% received ≥3 prior lines of chemotherapy, 18.0% had BRAF V600E mutation, and 56.0% had Lynch syndrome-related cancer. Seven patients (12.0%) discontinued treatment due to adverse events; one died due to a treatment-related adverse event. The disease control rate (DCR) at 12 weeks was 86.0% with RECIST 1.1% and 87.7% with iRECIST. Two pseudoprogressions (3.5%) were observed, at week 6 and at week 36, representing 18% of patients with disease progression per RECIST 1.1 criteria. With a median follow-up of 18.4 months, median progression-free survival (PFS) and overall survival (OS) were not reached. The 12-month PFS rate was 72.9% with RECIST 1.1% and 76.5% with iRECIST. The 12-month OS rate was 84%. Overall response rate was 59.7% with both criteria. RAS / BRAF status, sidedness, Lynch syndrome, and other baseline parameters were not associated with PFS. Conclusion Pseudoprogression is rare in patients with MSI/dMMR mCRC treated with nivolumab and ipilimumab. This combined ICI therapy confirms impressive DCR and survival outcomes in these patients. Trial registration number NCT03350126 .
A Physiologically Based Pharmacokinetic (PBPK) Model for Adults to Characterize BIVV001 Activity, a New Class of Factor VIII (FVIII) with High Sustained Factor Activity
Authors: Binfeng Xia, Suresh Katragadda, Donato Teutonico, Sreeraj Macha, Marek Demissie, Craig Benson
Journal: Blood (2020)
Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia
Authors: Anu Marahatta, Thad A. Howard, Susan E. Stuber, Kathryn L McElhinney, Leon Tshilolo, Thomas N. Williams, Peter Olupot-Olupot, Brigida Santos, Chandy C. John, Robert Opoka, Rosa M. Nieves, Rafael Mena, Jasmine Baker, Teresa Latham, Jonathan M. Flanagan, Russell E. Ware
Journal: Blood (2020)
NGS-Based Screening to Comprehensively Decipher TKIs Resistant Mutations in BCR-ABL1 Positive Leukemias
Authors: Hongxing Liu, Jiaqi Chen, Fang Wang, Jiancheng Fang, Wen Teng, Xue Chen, Yang Zhang, Xiaoli Ma, Panxiang Cao, Daijing Nie, Yu Li, Xiaosu Zhou
Journal: Blood (2020)
Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Authors: Kiyomi Morita, Kiran Naqvi, Guillermo Montalban Bravo, Philip A. Thompson, Koichi Takahashi, Yesid Alvarado, Elias Jabbour, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2020)
Prognostic Value of Computed Tomography–Derived Extracellular Volume in TAVR Patients With Low-Flow Low-Gradient Aortic Stenosis
Authors: Balaji Tamarappoo, Donghee Han, Jeffrey Tyler, Tarun Chakravarty, Yuka Otaki, Robert Miller, Evann Eisenberg, Siddharth Singh, Takahiro Shiota, Robert Siegel, Jasminka Stegic, Tracy Salseth, Wen Cheng, Damini Dey, Louise Thomson, Daniel Berman, John Friedman, Raj Makkar
Journal: JACC. Cardiovascular imaging (2020)
Increased FAPI Uptake in Brain Metastasis From Lung Cancer on 68Ga-FAPI PET/CT
Authors: Wenhui Fu, Lin Liu, Huipan Liu, Zhijun Zhou, Yue Chen
Journal: Clinical Nuclear Medicine (2020)

Abstract A 51-year-old woman with newly diagnosed lung cancer experienced progressive left hip pain for 1 month. 18 F-FDG PET/CT showed multiple hypermetabolic lesions throughout the body, including a suspicious lesion in the brain. Elevated FDG activity in select muscles was visualized, which was attributed to altered weight bearing. Unexpectedly, 68 Ga-fibroblast activation protein inhibitor PET/CT showed the FDG-avid lesion in the brain with excellent imaging contrast. Brain metastasis was confirmed by a cerebral MRI.
Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma
Authors: Beau M Idler, Olivia Perez De Acha, Owen Lockerbie, Ken Flanagan, Fredrik Lehmann, Peter A Forsberg, Tomer M Mark, Daniel W. Sherbenou
Journal: Blood (2020)
Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells
Authors: Viktoria Blumenberg, Maria-Luisa Schubert, Eli Zamir, Sabine Schmidt, Roman Rohrbach, Philipp Waldhoff, Daria Bozic, Hendrik Pock, Eran Elinav, Christian Schmidt, Veit Buecklein, Carsten Müller-Tidow, Peter Dreger, Michael von Bergwelt, Michael Schmitt, Marion Subklewe, Christoph Stein-Thöringer
Journal: Blood (2020)
Genotypic and Phenotypic Spectrum of Dyskeratosis Congenita: Results from the Canadian Inherited Marrow Failure Registry
Authors: Mohammed Al Nuaimi, Evelyn Elias, Albert Catala, Bozana Zlateska, Yeon Jung Lim, Robert J Klaassen, Geoff D.E. Cuvelier, Conrad Fernandez, Meera Rayar, MacGregor Steele, Sharon Abish, Yves D. Pastore, Vicky R. Breakey, Soumitra Tole, Josee Brossard, Roona Sinha, Mariana Silva, Lisa Goodyear, Jeffrey H. Lipton, Bruno Michon, Catherine Corriveau-Bourque, Lillian Sung, Yigal Dror, Michaela Cada
Journal: Blood (2020)
Only Hotspot <i>SF3B1</i> K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes
Authors: Rashmi Kanagal-Shamanna, Guillermo Montalban Bravo, Koji Sasaki, Carlos E. Bueso-Ramos, Elias Jabbour, Yue Wei, Faezeh Darbaniyan, Mark Routbort, Sherry A. Pierce, Kelly A. Soltysiak, Keyur Patel, L. Jeffrey Medeiros, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2020)
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis
Authors: Francesco Tovoli, Pietro Guerra, Massimo Iavarone, Letizia Veronese, Matteo Renzulli, Stefania De Lorenzo, Francesca Benevento, Giovanni Brandi, Federico Stefanini, Fabio Piscaglia
Journal: Liver Cancer (2020)

Due to its poor survival, intrahepatic cholangiocarcinoma (ICC) is held to be a much more aggressive cancer than hepatocellular carcinoma (HCC). In most published series, patients were diagnosed when symptomatic. However, ICC is now increasingly being discovered during the surveillance for HCC in cirrhosis. Whether this earlier detection of ICC is associated with an equally dismal prognosis or not is unknown.This is amulticenter retrospective study of consecutive ICC patients. Patients were stratified into subgroups according to the absence/presence of cirrhosis. A propensity score matching was performed to reduce the potential biases. Cirrhotic patients were further stratified according to their surveillance status. The lead-time bias and its potential effects were also estimated.We gathered 184 patients. Eighty-five patients (46.2%) were cirrhotic. Liver cirrhosis was not related to a worse overall survival (33.0 vs. 32.0 months, p = 0.800) even after the propensity score analysis (43.0 in vs. 44.0 months in 54 pairs of patients, p = 0.878). Among the cirrhotic population, 47 (55.3%) patients had received a diagnosis of ICC during a surveillance programme. The 2 subgroups differed in maximum tumour dimensions (30 vs. 48 mm in surveyed and non-surveyed patients, respectively). Surveyed patients were more likely to receive surgical treatments (59.8 vs. 28.9%, p = 0.003). Overall survival was higher in surveyed patients (51.0 vs. 21.0 months, p < 0.001). These benefits were confirmed after correcting for the lead-time bias.Cirrhotic patients have different clinical presentation and outcomes of ICC according to their surveillance status. In our series, ICC in cirrhosis was not associated with worse OS. Cirrhosis itself should not discourage either surgical or non-surgical treatments.
Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications
Authors: Ryosuke Shirasaki, Ricardo De Matos Simoes, Shizuka Yamano, Sondra L. Downey-Kopyscinski, Brian Glassner, Huihui Tang, Vikas Gupta, Aviad Tsherniak, Francisca Vazquez, Jonathan D. Licht, Larry H. Boise, Constantine S. Mitsiades
Journal: Blood (2020)
Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment
Authors: Igor Nicolas Novitzky-Basso, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Arjun Law, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Fotios Michelis, Dennis Dong Hwan Kim
Journal: Blood (2020)
Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry
Authors: Lisa La, Sundar Jagannath, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Hans C. Lee, Mohit Narang, James L. Omel, Robert M. Rifkin, Howard R. Terebelo, Kathleen Toomey, Lynne I. Wagner, Mazaher Dhalla, Liang Liu, Ling Yang, Prashant Joshi, Rafat Abonour
Journal: Blood (2020)
High EVI1 Expression Predict Adverse Outcome in Children with Acute Myeloid Leukemia: A Multicenter, Nonrandomized Clinical Study in China
Authors: Yongzhi Zheng, Jian Li, Xiaoqin Feng, Chunfu Li, Mincui Zheng, Honggui Xu, Yingyi He, Xiangling He, Jianda Hu
Journal: Blood (2020)
Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Eligible Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis
Authors: Zahoor Ahmed, Karun Neupane, Rabia Ashraf, Amna Khan, Abdul Rafae, Moazzam Shahzad, Muhammad Saad Farooqi, Sundas Ali, Saad Javed, Richi Kashyap, Shaha Nabeel, Faiz Anwer
Journal: Blood (2020)
Coronary Artery Calcium for Personalized Risk Management—A Second Chance for Aspirin in Primary Prevention?
Authors: Miguel Cainzos-Achirica, Philip Greenland
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial
Authors: Preetesh Jain, Yixin Yao, Shuangtao Zhao, Yang Liu, Holly Hill, Yuxuan Che, Yijing Li, Alexa A Jordan, Joseph McIntosh, Hun Ju Lee, Raphael Eric Steiner, Felipe Samaniego, Jason Westin, Loretta J. Nastoupil, Ranjit Nair, Sairah Ahmed, Chi Young Ok, Rashmi Kanagal-Shamanna, Onyeka Oriabure, Guofang Xu, Wendy Chen, Omar Moghrabi, Chloe Marie McClain, Maria Badillo, Selvi Thirumurthi, David Santos, Cezar Iliescu, C. Cameron Yin, Shaoying Li, Guilin Tang, Francisco Vega, Sattva S. Neelapu, Christopher Flowers, Linghua Wang, Michael Wang
Journal: Blood (2020)
International Society of Nephrology’s initiative on interventional nephrology minimum training and program-building standards in resource-limited countries
Authors: Tushar J. Vachharajani, Yong-Soo Kim, Miguel Riella, David Harris, Vivekanand Jha, Arif Asif, Gerasimos Bamichas, Brett Cullis, Colin Forman, Naveed Haq, Muzamil Hassan, Stephen May, Krishnaswamy Sampathkumar, Octavio Salgado
Journal: Kidney International (2020)
Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer
Authors: Masoud Farshbaf, Ahmad Yari Khosroushahi, Solmaz Mojarad-Jabali, Amir Zarebkohan, Hadi Valizadeh, Paul R. Walker
Journal: Journal of Controlled Release (2020)

As one of the deadliest diseases, cancer frequently resists existing therapeutics because they do not target all cells within a progressing tumor, for example both tumor stem and proliferating cells. This frequently results in enrichment of invasive and metastatic drug-resistant tumor cells subpopulations, cancer recurrence and eventually, patient mortality. Thus, there is an urgent need to identify specific markers, by which the targeted imaging and/or therapeutic "guided missile"-like agents can specifically detect and/or eradicate all cancer cells within a heterogeneous tumor, while leaving the normal cells intact. As a member of heat shock protein 70 (HSP70) superfamily, glucose regulated protein 78 (GRP78) has been documented as a molecular chaperone in the endoplasmic reticulum (ER) which mainly responds to ER stresses in normal cells. There is over-expression of GRP78 on the surface of cancer cells and angiogenic endothelial cells, which makes it a promising target for different types of peptides and antibodies that can be employed for targeted cancer therapy or imaging. In this review, we discuss the biological processes, functional importance and translocation mechanisms of cell surface GRP78 (csGRP78) in tumor cells. As a cancer biomarker, we also review the potential applications of csGRP78 targeted therapy and imaging and finally we suggest a brief roadmap ahead of csGRP78 targeting for targeted theranostic implications.
Hemorrhagic Cerebral Vascular Accident with Breakdown of Salt-Wasting Cerebral Syndrome in Acute Lymphoblastic Leukemia: Case Report
Authors: Hugo Henrique de Freitas Ferreira, Alessandra Suelen Jardim Silva, Lenilton Silva DA Silva Júnior, Gustavo Henrique de Medeiros Oliveira, Maria das Graças Pereira Araujo, Victor lima Soares, Frank Bahia, Taissa Moura Oliveira, Dany GKC Silva, Valéria SF Sales, Aldair Sousa Paiva, Geraldo Barroso Cavalcanti
Journal: Blood (2020)
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
Authors: Hassan Dana, Ghanbar Mahmoodi Chalbatani, Seyed Amir Jalali, Hamid Reza Mirzaei, Stephan A. Grupp, Eloah Rabello Suarez, Catarina Rapôso, Thomas J. Webster
Journal: Acta Pharmaceutica Sinica B (2020)

New approaches to cancer immunotherapy have been developed, showing the ability to harness the immune system to treat and eliminate cancer. For many solid tumors, therapy with checkpoint inhibitors has shown promise. For hematologic malignancies, adoptive and engineered cell therapies are being widely developed, using cells such as T lymphocytes, as well as natural killer (NK) cells, dendritic cells, and potentially others. Among these adoptive cell therapies, the most active and advanced therapy involves chimeric antigen receptor (CAR)-T cells, which are T cells in which a chimeric antigen receptor is used to redirect specificity and allow T cell recognition, activation and killing of cancers, such as leukemia and lymphoma. Two autologous CAR-T products have been approved by several health authorities, starting with the U.S. Food and Drug Administration (FDA) in 2017. These products have shown powerful, inducing, long-lasting effects against B cell cancers in many cases. In distinction to the results seen in hematologic malignancies, the field of using CAR-T products against solid tumors is in its infancy. Targeting solid tumors and trafficking CAR-T cells into an immunosuppressive microenvironment are both significant challenges. The goal of this review is to summarize some of the most recent aspects of CAR-T cell design and manufacturing that have led to successes in hematological malignancies, allowing the reader to appreciate the barriers that must be overcome to extend CAR-T therapies to solid tumors successfully.
Abstract 455: The Roles of VEGF Receptors in Human Cardiac Progenitor Cell Contribution to New Vascular Formation
Authors: Hanqing Zhao, Sreenivasan Ponnambalam, Andrew J Smith
Journal: Circulation Research (2020)

Background: Human cardiac progenitor cells (CPCs) have been shown to play a valuable role in myocardial tissue maintenance, including their ability to develop into endothelial and vascular smooth muscle cells. The vascular endothelial growth factor (VEGF) ligand family has been identified as essential for angiogenesis. VEGF receptors (VEGFRs) comprise three main subtypes, VEGFRs1,2,3; our prior data identified CPC expression of both VEGFRs and of pro-angiogenic secreted growth factors. Hypothesis: Human CPCs utilise VEGFR signalling to potentiate CPC-driven angiogenesis, directly via CPC differentiation and indirectly via secrotome. Methods: Human adult myocardial tissue samples were collected during cardiac surgery and c-Kit-positive (c-Kit + ), CD45-negative (CD45 - ) CPCs isolated by immunomagnetic bead sorting, with five CPC lines generated from individual-donor samples. The c-Kit + / CD45 - CPC population was then characterised by clonogenicity assay, immunocytochemistry (ICC), and real-time RT-qPCR. Human CPC lines were FACS sorted into 3 lineage groups: endothelial (CD31 + ), smooth muscle (CD91 + /CD140b + /CD31 - ) and uncommitted (CD91 - /CD140b - /CD31 - ). Expression of VEGFRs and markers (SDF1; TGF-β) in CPC sub-populations was assessed by: qPCR; Western blot; ICC. Impact on signal transduction by VEGF-A stimulation was identified by Western blot and ICC. Results: Human CPCs were sorted into populations of: endothelial linage CD31 + (1.26% of total cells), smooth muscle lineage CD91 + /CD140b + /CD31 - (13.77%) and CD91 - /CD140b - /CD31 - (31.28%) cells. Analysis of gene expression identified VEGFRs 1, 2 and 3 in all three sub-populations, but only VEGFR1 expression was confirmed at protein level, seen in all three sub-populations. High expression levels of growth factors secreted by CPCs (SDF, TGF-β, VEGFs, FGF-2) were identified in human CPCs, also in all three sub-populations. Conclusion: Human CPC lines were isolated and analysed in bulk and sub-populations, identifying VEGFR1 expression at both gene and protein levels, but not VEGFR2 and VEGFR3. Our further work will identify signalling pathways in human CPCs linked to VEGF-A stimulation, along with the impact of VEFG-A stimulation on CPC secretome and linked angiogenic potential.
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
Authors: Ilaria J. Chicca, Jennifer L. J. Heaney, Gulnaz Iqbal, Janet A. Dunn, Stella Bowcock, Guy Pratt, Kwee L. Yong, Timothy D. Planche, Alex Richter, Mark T. Drayson
Journal: Blood Cancer Journal (2020)

Abstract Multiple myeloma (MM) is associated with increased risk of infection, but little is known regarding antibody levels against specific bacteria. We assessed levels of polyclonal immunoglobulin and antibacterial antibodies in patients recruited to the TEAMM trial, a randomised trial of antibiotic prophylaxis at the start of anti-myeloma treatment. Polyclonal IgG, IgA and IgM levels were below the reference range in 71%, 83% and 90% of 838 MM patients at diagnosis. Anti-vaccine targeted tetanus toxoid antibodies were protective in 95% of 193 healthy controls but only 41% of myeloma patients. In healthy controls, protective antibodies against 6/12 pneumococcal serotypes, haemophilus and meningococcus A were present in 67%, 41% and 56% compared to just 15%, 21% and 17% of myeloma patients. By 1 year, myeloma patients IgG levels had recovered for 57% of patients whilst the proportion with protective levels of IgG against thymus-dependent protein antigen tetanus toxoid had changed little. In contrast the proportions of patients with protective levels against thymus independent polysaccharide antigens pneumococcus, haemophilus and meningococcus had fallen from 15 to 7%, 21 to 0% and 17 to 11%. Findings highlight the need for strategies to protect patients against bacterial infections during therapy and vaccination programmes during remission.
Addressing Social Determinants of Liver Disease During the COVID‐19 Pandemic and Beyond: A Call to Action
Authors: Ani Kardashian, Julius Wilder, Norah A. Terrault, Jennifer C. Price
Journal: Hepatology (2020)

The COVID‐19 pandemic has exposed healthcare inequities in the USA and highlighted the importance of social conditions in shaping the health of persons. In the field of hepatology, social determinants of health (SDOH) are closely linked to disparities in liver disease prevalence, outcomes, and access to treatment. The economic disruption and physical distancing policies brought on by the COVID‐19 pandemic have further exacerbated these disparities, and may have long‐lasting health consequences for marginalized patients with chronic liver disease. There are several ways that hepatology providers can bridge the gap in health equity through addressing SDOH, extending from the individual to the community and societal levels. Interventions at the individual level include implementation of systematic screening for social barriers in our hepatology practices to identify gaps in the care cascade. At the community and societal levels, interventions include creating collaborative partnerships with public health workers to expand healthcare access to the community, increasing funding for research investigating the association of SDOH, health disparities, and liver disease, engaging in advocacy to support policy reform that tackles the upstream social determinants, and addressing racism and implicit bias. As hepatology practices adapt to the “new normal,” now is the time for us to address our patients’ social needs within the context of healthcare delivery and reimagine ways in which to provide care to best serve our most vulnerable patients with liver disease in the COVID‐19 era and beyond.
A Phase 1 Study of HMPL-689, a Small Molecule, Highly Selective, and Potent Inhibitor of Phosphoinositide 3 Kinase-Delta, in Patients with Relapsed or Refractory Lymphoma
Authors: Tunde Lawrence, Marjo Hahka-Kemppinen, Jonathon B. Cohen, Marek Kania
Journal: Blood (2020)